

Michael Saborowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/558638/publications.pdf>

Version: 2024-02-01

20
papers

1,976
citations

623734

14
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

5081
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor \hat{I}^2 Signaling. <i>Cell</i> , 2014, 157, 382-394.	28.9	412
2	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 689-713.	5.4	351
3	Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors. <i>Cancer Cell</i> , 2014, 25, 697-710.	16.8	238
4	Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. <i>Science Translational Medicine</i> , 2015, 7, 271ra7.	12.4	236
5	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. <i>Molecular Therapy</i> , 2015, 23, 1630-1640.	8.2	165
6	Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. <i>Genome Research</i> , 2015, 25, 714-724.	5.5	115
7	Conditional Reverse Tet-Transactivator Mouse Strains for the Efficient Induction of TRE-Regulated Transgenes in Mice. <i>PLoS ONE</i> , 2014, 9, e95236.	2.5	79
8	A modular and flexible ESC-based mouse model of pancreatic cancer. <i>Genes and Development</i> , 2014, 28, 85-97.	5.9	70
9	Mouse model of intrahepatic cholangiocarcinoma validates FIG \hat{A} ROS as a potent fusion oncogene and therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19513-19518.	7.1	66
10	Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. <i>Gastroenterology</i> , 2016, 151, 338-350.e7.	1.3	65
11	Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 \hat{A} T Cell Responses against Cancer. <i>Cell Reports</i> , 2016, 17, 2234-2246.	6.4	57
12	Arid1a restrains Kras-dependent changes in acinar cell identity. <i>ELife</i> , 2018, 7, .	6.0	39
13	Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro. <i>Hepatology Communications</i> , 2019, 3, 423-436.	4.3	25
14	Clinical characteristics of patients with liver cirrhosis and spontaneous portosystemic shunts detected by ultrasound in a tertiary care and transplantation centre. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1107-1113.	1.5	18
15	The Co \hat{A} mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion \hat{A} Driven Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1357-1370.	7.3	13
16	Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. <i>Cancers</i> , 2019, 11, 1904.	3.7	11
17	Generation of focal mutations and large genomic deletions in the pancreas using inducible <i>in vivo</i> genome editing. <i>Carcinogenesis</i> , 2020, 41, 334-344.	2.8	7
18	Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research. <i>Cancers</i> , 2019, 11, 1868.	3.7	5

#	ARTICLE	IF	CITATIONS
19	p53-Independent Induction of p21 Fails to Control Regeneration and Hepatocarcinogenesis in a Murine Liver Injury Model. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1387-1404.	4.5	3
20	Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2137-2144.	2.5	1